Immunohistochemical Determination of HER-2/neu in Malignant Melanoma

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 4067-4069

  Potti, Anil ^a   Hille, Rachel ^a   Koch, Michael ^b  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b MeritCare Hospital   (United States)

Author keywords

HER 2 neu; Malignant melanoma; Onco protein; Overexpression

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYTOKINE; DACARBAZINE; VINCRISTINE;

ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOGENESIS; MELANOMA; ONCOGENE NEU; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 0345305205     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kopf AW, Salopek TG, Slade J, Marghoob AA and Bart RS: Techniques of cutaneous examination for the detection of skin cancer. Cancer 75: 684-90, 1995.
2. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-12, 1990.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Fress MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-12, 1989.
4. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL and Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-6, 1994.
5. Tsugawa K, Fushida S and Yonemura Y: Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. Oncology 50: 418-25, 1993.
6. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS and Podratz KC: HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179-85, 1992.
7. Hiesiger EM, Hayes RL, Pierz DM and Budzilovich GN: Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-erbB-2 expression in glioblastomas (GBMs). J Neurooncol 16: 93-104, 1993.
8. Easty DJ, Herlyn M and Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60: 120-36, 1995.
9. Chenevix-Trench G, Martin NG and Ellem KAO: Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53. Oncogene 5: 1187-93, 1990.
10. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E and Kiessling R: Identification of HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogenic carcinomas and melanomas. J Immunology 163: 1037-44, 1999.
11. Ramachandra S, Gillett CE and Millis RR: A comparative immunohistochemical study of mammary and extramammary Paget's disease and superficial spreading melanoma, with particular emphasis on melanocytic markers. Virchows Arch 429: 371-6, 1996.
12. Jimenez RE, Wallis T, Tabasczka P and Visscher DW: Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13: 37-45, 2000.
13. Buehler H, Bangemann N, Evers K, Becker C and Schaller G: Effective HER-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH [abstract]. Proc Am Soc Clin Oncol 19: a76, 2000.
14. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-81, 1958.
15. Persons DL, Arber DA, Sosman JA, Borelli KA and Slovak ML: Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Anticancer Res 20: 1965-8, 2000.
16. Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR and Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319-30, 1997.
17. Press MF, Hung G, Godolphin W and Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-7, 1994.